Advertisement
Advertisement
ACLX
Arcellx, Inc. Common Stock
114.83
USDSponsored
+0.03
+0.03%
Apr 10, 15:59 UTC -4
Closed
Pre-Market
114.83
0.00
0.00%
ACLX Earnings Reports
Positive Surprise Ratio
ACLX beat 7 of 17 last estimates.
41%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$6.25M
/-$1.13
Implied change from Q4 25 (Revenue/ EPS)
+277.94%
/+11.88%
Implied change from Q1 25 (Revenue/ EPS)
-23.10%
/+0.89%
Arcellx, Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, ACLX reported earnings of -1.01 USD per share (EPS) for Q4 25, beating the estimate of -1.05 USD, resulting in a 4.54% surprise. Revenue reached 1.65 million, compared to an expected 13.67 million, with a -87.90% difference. The market reacted with a -0.08% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of -1.13 USD, with revenue projected to reach 6.25 million USD, implying an increase of 11.88% EPS, and increase of 277.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Fortress Biotech, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.11
Actual
-$0.01
Surprise
-108.91%
OS Therapies Incorporated
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.50
Surprise
-260.49%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Arcellx, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Arcellx, Inc. Common Stock reported EPS of -$1.01, beating estimates by 4.54%, and revenue of $1.65M, -87.9% below expectations.
How did the market react to Arcellx, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -0.08%, changed from $113.88 before the earnings release to $113.79 the day after.
When is Arcellx, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Arcellx, Inc. Common Stock's next earnings report?
Based on 12
analysts, Arcellx, Inc. Common Stock is expected to report EPS of -$1.13 and revenue of $6.25M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement